Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.

被引：0
|
作者：
Suvannasankha, A [1 ]
Smith, GG [1 ]
Abonour, R [1 ]
机构：
[1] Indiana Univ, Ctr Canc, Sch Med, Indianapolis, IN 46204 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2562
引用
收藏
页码：720A / 720A
页数：1
相关论文
共 50 条
  • [21] Bortezomib in relapsed or refractory myeloma patients
    Leonetti Crescenzi, S.
    Piccioni, A. L.
    Bagnato, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 208 - 208
  • [22] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
    Leleu, X
    Troncy, J
    Micol, JB
    Bouafia, F
    Guieze, R
    Yakoub-Agha, I
    Depil, S
    Kuhnovski, F
    Terriou, L
    Michallet, M
    Facon, T
    Dumontet, C
    BLOOD, 2003, 102 (11) : 384B - 384B
  • [24] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
    Lonial, Sagar
    Francis, Dixil
    Karanes, Chatchada
    Trudel, Suzanne
    Dollard, Akari M.
    Aceo, Fermin
    Gul, Engin
    Kakar, Sumeet
    Krishnan, Amrita Y.
    Reece, Donna E.
    Harvey, R. Donald
    Kaufman, Jonathan L.
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [26] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    Kovalchuk, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 616 - 616
  • [28] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 590 - 590
  • [29] Combination chemotherapy including velcade in patients with refractory or relapsed multiple myeloma.
    Zhou, YuHong
    Yu, QingHong
    Hu, ZhiPing
    Ye, BaoDong
    Shen, YiPing
    Shen, JianPing
    Yu, LongXi
    BLOOD, 2006, 108 (11) : 361B - 362B
  • [30] Bortezomib in relapsed or refractory multiple myeloma:: results in a cohort of 39 patients
    Canovas Fernandez, A.
    Alonso Alonso, J. J.
    Barreiro Garcia, J. G.
    Aguirre Errasti, C.
    REVISTA CLINICA ESPANOLA, 2008, 208 (04): : 187 - 192
12345